Package leaflet: Information for the patient
SCENESSE 16 mg implant afamelanotide
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
-Keep this leaflet. You may need to read it again.
-If you have any further questions, ask your doctor.
-If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4.
What is in this leaflet
1.What SCENESSE is and what it is used for
2.What you need to know before you receive SCENESSE
3.How SCENESSE is given
4.Possible side effects
5.How SCENESSE is stored
6.Contents of the pack and other information
1.What SCENESSE is and what it is used for
SCENESSE is a medicine that contains the active substance afamelanotide. Afamelanotide is a synthetic form of a body hormone called
Afamelanotide is used to increase the tolerance to sunlight in adults with a confirmed diagnosis of erythropoietic protoporphyria (EPP). EPP is a condition in which patients have an increased sensitivity to sunlight, which can cause toxic effects such as pain and burning. By increasing the amount of eumelanin, SCENESSE can help to delay the onset of pain due to skin photosensitivity (sensitive to sunlight).
2. What you need to know before you use SCENESSE
Do not use SCENESSE
-if you are allergic to afamelanotide or any of the other ingredients of this medicine (listed in section 6).
-if you have any severe condition of the liver.
-if you have liver problems.
-if you have kidney problems.
Warnings and precautions
Talk to your doctor before using SCENESSE if you have or have ever had:
-heart problems (including an irregular heart beat) or severe breathing problems (such as asthma or bronchitis)
-Cushing’s disease (a hormone disorder where the body produces too much of the hormone cortisol)
-Addison’s disease (a disorder of the adrenal glands causing a lack of some hormones)
-epilepsy (or have been told that you are at risk of having fits)
-anaemia (low counts of red blood cells in your blood).
-melanoma (an aggressive type of skin cancer), including
-skin cancer of the types, basal cell carcinoma or squamous cell carcinoma (inclusive of carcinoma in situ, e.g. Bowen’s disease), Merkel cell carcinoma or other malignant or premalignant skin problems.
Talk to your doctor before using SCENESSE if you are over 70 years of age.
If you have ever had any of these conditions your doctor may have to monitor you more closely during your treatment.
Do not change the sun protection measures you normally follow to manage your EPP and according to your skin phototype (UV sensitivity). Keep in mind that increased exposure to UV light will contribute to skin cancer development.
Because this medicine increases eumelanin, in most treated patients the skin will darken. This is an expected response to this medicine, and the darkening will slowly fade unless another implant is used.
Your doctor will need to regularly check your skin (full body) to monitor changes in moles (e.g. darkening) or other skin abnormalities. This is recommended to be performed every 6 months.
Please inform your doctor about new or changing skin abnormalities. Arrange for an early appointment with your porphyria specialist if pigmented lesions like moles grow or if other growing,
Children and adolescents
This medicine should not be given to children and adolescents between the ages of 0 and under 18 years because it has not been tested in this age group.
Other medicines and SCENESSE
Tell your doctor if you are taking, have recently taken or might take any other medicines.
Tell your doctor if you are taking anticoagulant medicines used to prevent blood clots. These may include warfarin, acetylsalicylic acid (a substance present in many medicines used to relieve pain and lower fever or to prevent blood clotting) and a group of medicines called
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, you should not receive SCENESSE, since it is not known how it will affect your unborn baby or the breastfed infant.
Women who could become pregnant should use adequate contraception such as oral contraceptives, diaphragm plus spermicide, intrauterine device (also known as a coil) during treatment and for three months after the last SCENESSE implantation.
Driving and using machines
There is a risk of feeling drowsy and tired when using this medicine, especially within 72 hours of administration. If you are affected, do not drive or use any tools or machines. If you suffer from continued drowsiness, then you should speak to your doctor.
3. How to use SCENESSE
The implant will be inserted by a doctor who has been trained in the administration procedure. The doctor will decide with you the most suitable time and the site for inserting the implant.
One implant is injected every 2 months during the spring and summer months. Three implants per year are recommended, depending on the length of effect required. However, this number should not exceed more than 4 per year.
The implant is given as injection under your skin using a catheter tube and needle (subcutaneous use). Before inserting this medicine, your doctor may decide to give you a local anaesthetic to numb the area where the implant is to be inserted. The implant is inserted directly under the skin folds on your waist or abdomen in an area known as the
At the end of the insertion procedure, you may be able to feel the implant under your skin. Over time the implant will be absorbed by the body, this will happen within 50 to 60 days after implantation.
If you experience discomfort and are concerned, speak to your doctor. The implant may be removed by a simple surgical procedure if needed.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4.Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The following side effects are considered to be:
Very common (may affect more than 1 in 10 people):
Nausea (feeling sick), headache; reactions at the implant site including pain, redness, itching, bruising and changes to colour of overlying skin.
Common (may affect up to 1 in 10 people):
General changes to the skin including freckles and skin darkening; migraine (a severe headache); back pain; abdominal (tummy) pain, diarrhoea and vomiting, decreased appetite; fatigue (tiredness), dizziness, drowsiness and weakness; hot flushes; upper respiratory tract infections (colds).
Uncommon (may affect up to 1 in 100 people):
-Infected hair follicle, fungal infection, urinary tract infection
-Chills, fever, flu,
-Depression, inability to sleep, poor quality sleep, fainting, fainting sensation, fall, hangover, weakness, inability to get legs comfortable, increased sensitivity to touch, headache following injury, burning sensation, abnormal taste sensation
-Swollen eye lids, red eyes, dry eye, difficulty focusing on close objects, ringing in ears
-Palpitations, fast heart rate, bruising, high blood pressure, difficulty to make some sounds
-Inflamed lips, lip swelling, colouration on lip, gum pain, toothache, discoloured gums, reduced sense of touch in mouth, lip discolouration, tongue discolouration
-Increased hunger, nausea following implant insertion, indigestion, infection in stomach and intestines, inflamed stomach and intestines, heartburn ,inflamed stomach, irregular bowel movements, wind, bloated tummy, tummy pain
-Irregularity of skin, rash with small blisters, itch, rash, red rash, red swelling on skin, rash with small bumps, itchy rash, skin irritation, lighter skin patches, acne, eczema, secretions on skin, skin peeling, skin with loss of colour, hair colour changes, excessive sweating
-Joint pain, muscle pain, pain in arms and legs, sudden muscle contraction, pain in muscles and bones, stiffness of muscles and bones, joint stiffness, groin pain, feeling of heaviness, swelling in lower limbs
-Heavy and prolonged period, abnormal period, breast tenderness, irregular periods, discharge from vagina, decreased sex drive
-Pain, swelling around site of implantation, bruising at injection site, irritation at injection site, enlargement at implant site, itching at implant site, implant falling out, change in colour of skin at implant site
-Decrease white blood cells, abnormal liver function tests, decreased iron binding, increased cholesterol, increased sugar level, decreased blood iron level, increased blood pressure, blood in urine
-Wound complication, open wound
Reporting of side effects
If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
5.How SCENESSE is stored
Keep this medicine out of the sight and reach of children.
This medicine must not be used after the expiry date which is stated on the vial and the outer carton. Your doctor will check the expiry date before an implant is used.
Store in a refrigerator (2oC - 8oC)
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information
What SCENESSE contains
The active substance is afamelanotide. One implant contains 16 mg of afamelanotide. The other ingredient is poly
What SCENESSE looks like and contents of the pack
The implant is a solid white to
Pack size of one vial containing one implant.
Marketing Authorisation Holder
Clinuvel (UK) Limited
60 Goswell Road
London EC1M 7AD
Tel: +44 (0)20 7566 4000
Fax: +44 (0)20 7566 4010
Catalent UK Packaging Ltd
Wingates Industrial Estate
Lancashire BL5 3XX
This leaflet was last revised in
This medicine has been authorised under ‘exceptional circumstances’. This means that because of the rarity of this disease it has been impossible to get complete information on this medicine.
The European Medicines Agency will review any new information on this medicine every year and this leaflet will be updated as necessary.
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu. There are also links to other websites about rare diseases and treatments.
The following information is intended for healthcare professionals only:
Method of administration
SCENESSE is administered subcutaneously under aseptic conditions as described below. Administration should be performed by a physician trained and accredited by the marketing authorisation holder to administer the implant.
Instruction for use
-Take the packed implant out of the refrigerator and allow the medicinal product to warm up to ambient temperature.
-Have the patient sit in a comfortable position or lie on his/her back with the upper part of the body slightly raised.
-Disinfect the skin above the
-Anaesthetize the insertion area if deemed necessary and in consultation with the patient.
-Select a 14 gauge (1.6 mm inner diameter) catheter with needle.
-Mark 1.5 to 2 cm on the catheter shaft using surgical ink.
-Hold the catheter at its base using a sterile technique, pinch and hold the skinfold cranial to, or overlying the patient’s
-With the bevel of the needle facing upwards, insert the catheter laterally 1.5 to 2 cm into the subcutaneous layer at a 30 to 45 degree angle to the skin surface in one continuous flowing movement.
-With the catheter in place, aseptically remove the implant from the vial.
-Remove the needle from within the catheter using a sterile technique.
-Transfer the implant to the outlet of the catheter.
-Using a suitable device (such as a stylet) gently push the implant down the full length of the catheter lumen.
-Apply some pressure to the insertion area with your finger while removing the stylet and the catheter.
-Confirm insertion of the implant by palpating the skin with subcutis cranial to/overlying the suprailiac crest until the implant is located. Always verify the presence of the implant, if in doubt of its presence, check whether the implant has remained in the catheter. If the implant has not been administered during the procedural steps described above, discard the implant and administer a new implant. Do not administer a new implant unless it has been unequivocally confirmed that the first one had not been inserted.
-Apply a small pressure dressing to the injection site.
-Observe the patient for 30 minutes to ensure that you will notice if the patient develops an allergic or hypersensitivity reaction (immediate type).
The implant can be surgically removed if needed.
Conclusions on the granting of the marketing authorisation under exceptional circumstances presented by the European Medicines Agency
Conclusions presented by the European Medicines Agency on:
•Marketing authorisation under exceptional circumstances
The CHMP having considered the application is of the opinion that the